Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with Autologous Stem Cell Transplantation in Multiple Myeloma
NCT03292263Phase 2Active, not recruiting
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Apr 2017
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in multiple myeloma (MM), sponsored by First Saint Petersburg State Medical University. Primary endpoint: Overall Response at 3 months. Started Apr 2017; status: active, not recruiting.
02
Drugs
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03292263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292263.